Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

PartnershipIdefirixPositive

AI Analysis

Summary

Hansa Biopharma closed a €115 million licensing transaction with SERB Pharmaceuticals, transferring commercialization rights for Idefirix in Europe, MENA, and select countries. The deal significantly strengthens Hansa's financial position and supports its planned US launch, pending approval.

Financial Highlights

Revenue

€115 million

Outcome Details

Licensing transaction closed for commercialization rights in EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA

Importance:7/10

Sentiment:

0.70

licensing dealpartnershipcommercializationgeographic expansionfinancial strengthening

Related Companies

$HNSA.ST

Read the original article

Published by PR Newswire Pharma on July 1, 2026 1:15 PM

Read Original